Due to health issues, this site is no longer maintained and will be shut down shortly. |
GBS Inc. is on a mission to put the power of non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help eradicate COVID-19 and change the lives of people living with diabetes.
$0.31
As of 12/09/2022 IEX book CBOE book
2022 © Stock Market MBA, Inc.